CytoDyn Describes Stunning Results for COVID-19 Treatment with Leronlimab; Drug Ends “Cytokine Storms,” Restores Lung Function, & Reduces Plasma Viral Load; Ventilated Patients Achieve Rapid Improvement & Some Can Be Ex-Tubated 48 Hours After Treatment

--Results described in CytoDyn Investor Community Conference Call on Monday, April 27, 2020. --CytoDyn scientists believe their studies show that powerful immune modulator RANTES drives the pathogenic process of COVID-19. --RANTES is chemoactive chemokine, expressed by many hematopoietic and non-hematopoietic cell types, that plays key role in controlling homing and migration of effector and memory T-cells during acute infections. --RANTES receptor (CCR5) is co-receptor for HIV and a major target of anti-HIV drugs based on blocking viral entry. --RANTES levels are highly elevated in COVID-19 patients and RANTES fundamentally drives the COVID-19 pathogenic process via binding of RANTES to CCR5. --CytoDyn’s drug, a humanized monoclonal antibody called leronlimab, blocks CCR5, denying binding access to RANTES. --Levels of RANTES return to normal very quickly after single sub-cutaneous injection of leronlimab --Disease-associated high levels of interleukin-6, and of other chemokines, are quickly reduced to normal. --Lung function is restored. --Plasma viral load is reduced. --Drug delivered by one subcutaneous injection.
Login Or Register To Read Full Story